Eli Lilly (LLY) stock plunges as Phase 3 trial data for the company's oral weight loss drug orforglipron overshadow better ...

It's been a sad week for Organon & Co. ( NYSE:OGN ), who've watched their investment drop 13% to US$8.72 in the ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. Eli Lilly also released long-awaited ...

A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.

Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster ...

Prestige Consumer Healthcare expects full-year earnings to be $4.50 to $4.58 per share, with revenue in the range of $1.1 billion to $1.12 billion. This story was generated by Automated Insights ( ...

Dentsply expects full-year earnings in the range of $1.80 to $2 per share, with revenue in the range of $3.6 billion to $3.7 billion. This story was generated by Automated Insights ( ...

So far this earnings season, companies in the S&P 500 that miss Wall Street's estimates for earnings per share and sales have ...

With its 4-star rating, we believe Microsoft’s stock is undervalued compared with our long-term fair value estimate of $600 per share, which implies a fiscal 2026 enterprise value/sales multiple of 14 ...

Robinhood is experiencing robust earnings momentum, expanding its customer base, and making significant moves in the booming ...

Key Points MetLife's adjusted earnings per share (Non-GAAP) fell to $2.02, missed estimates by 6.0% (non-GAAP) and declining 11% from the prior year (non-GAAP, Q2 2025 vs. Q2 2024). Revenue (GAAP) was ...

For its 2025-27 business plan, Mercari aims to achieve double-digit CAGR for revenue, and above 25% CAGR for operating profit. We think the top-line goal seems to be a stretch, but the profit growth ...